Spero Therapeutics, Inc. Common Stock
$1.12
$0.01 (+0.90%)
$1.11Day Range$1.14
Key Statistics
Market Cap
$65.22M
Shares Outstanding
58.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 2, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$1.14
Day High
$1.14
Day Low
$1.11
Volume
181.8K
VWAP
$1.12
Prev Close
$1.11
Transactions
--
Acc. Volume
--
About Spero Therapeutics, Inc. Common Stock
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
PHARMACEUTICAL PREPARATIONSSIC 283425 employees675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02139857-242-1600IPO Nov 2, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001701108
- Composite FIGI
- BBG00HXSJ1R2
- Share Class FIGI
- BBG00HXSJ1S1
- Ticker Root
- SPRO
- SIC Code
- 2834
About Spero Therapeutics, Inc. Common Stock (SPRO) Stock
Spero Therapeutics, Inc. Common Stock (SPRO) closed the 2026-09-17 session at $1.12, up 0.90% versus the previous close (+0.01). The stock opened at $1.14 and traded between $1.11 and $1.14 during that session. Session trading volume was 182K shares. The volume-weighted average price (VWAP) is $1.12.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics, Inc. Common Stock has a market capitalization of $65.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SPRO is listed on the XNAS exchange. The company employs approximately 25 people. Spero Therapeutics, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2017-11-02.
On this page you can find market SPRO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.